Abstract
Age-related macular degeneration (AMD) is a major cause of irreversible vision loss in the elderly. Although new therapies have recently emerged, there are currently no ways of preventing the development of the disease. Changes in intracellular recycling processes. Changes in intracellular recycling processes, called autophagy, lead to debris accumulation and cellular dysfunction in AMD models and AMD patients. Drugs that enhance autophagy hold promise as therapies for slowing AMD progression in preclinical models; however, more studies in humans are required. While a definitive cure for AMD will likely hinge on a personalized medicine approach, treatments that enhance autophagy hold promise for slowing vision loss.
| Original language | English |
|---|---|
| Article number | 102463 |
| Pages (from-to) | 1-11 |
| Journal | Current Opinion in Pharmacology |
| Volume | 76 |
| DOIs | |
| Publication status | Published - 30 Jun 2024 |
Fingerprint
Dive into the research topics of 'Pharmaceutical therapies targeting autophagy for the treatment of age-related macular degeneration'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver